MHRA advice pauses PATHWAYS puberty blockers trial

On 20 February 2026, the Department of Health and Social Care confirmed that preparatory work for the PATHWAYS clinical trial - the planned NHS‑supported study of puberty‑suppressing medicines for children and young people with gender incongruence - has been paused after the medicines regulator, the MHRA, raised new concerns. No young people will be recruited until those issues are worked through with the trial’s clinicians and sponsor. (gov.uk)

If you’re a teacher or parent trying to keep track, ‘paused’ means the research is on hold while the regulator and King’s College London, which sponsors the study, meet to review the concerns. Officials have been clear that the trial can only go ahead if expert advice concludes it is both safe and necessary. A separate note from the Health Research Authority confirms the study will be re‑reviewed by an independent Research Ethics Committee before any restart. (gov.uk)

Today’s care pathways do not change. NHS England’s national clinical policy, published on 12 March 2024, states puberty blockers are not routinely available for under‑18s outside research. In December 2024, the government made indefinite restrictions on private and EEA prescriptions for under‑18s, with a review due in 2027. The PATHWAYS trial is the intended research route; for now, it is simply not opening to participants. (gov.uk)

So what would PATHWAYS study? King’s College London describes a randomised trial comparing starting gonadotrophin‑releasing hormone agonists (puberty blockers) straight away with starting after 12 months, alongside linked studies that follow development and wellbeing over time. The Health Research Authority’s summary notes plans for about 226 participants under 16, recruited through NHS children’s gender services, with independent oversight committees in place. (kcl.ac.uk)

Why did the regulator step in? The MHRA’s job is to make sure medicines studies are safe and scientifically sound. The Guardian reports the agency has recommended tightening the protocol, including raising the minimum age to 14 and taking a stepwise approach. Those details have not been published by the regulator, so treat them as reporting to be confirmed in official updates. (theguardian.com)

What happens procedurally is straightforward but important. If the MHRA asks for substantial amendments, the sponsor submits changes; an independent Research Ethics Committee then reviews whether the study remains ethically and scientifically acceptable. The HRA has said it will do this review before any restart because the study is paused. (hra.nhs.uk)

It helps to place this pause on a timeline you can use in class. In April 2024, after the Cass Review’s final report, NHS England moved to a new service model, closed the old Tavistock GIDS on 31 March, and opened two regional services on 1 April. The government later made private and overseas prescriptions for blockers in under‑18s indefinitely restricted. Research like PATHWAYS was proposed to build a better evidence base. (england.nhs.uk)

When you read claims online, remember that ‘paused’ is not ‘cancelled’, and that different groups disagree about benefits and risks. Dr Hilary Cass’s review underlined that the evidence for blockers in this age group is limited and called for higher‑quality studies; the NHS response adopted a more cautious, evidence‑first approach. So this pause is the system applying that principle. (england.nhs.uk)

If you support a young person, the immediate takeaway is simple: no one is being asked to join a study right now. Keep conversations calm, stick to trusted sources, and speak with your GP or school mental health lead if worries grow. Official updates from DHSC, MHRA, the HRA and King’s College London will set out any changes to eligibility or timelines. (gov.uk)

When the trial documentation is updated, look for plain‑English answers to common classroom questions: Who can take part and at what ages? How will bone health, fertility and mental health be monitored? Who stops the study if problems arise? And what happens after the trial ends so care is continuous? Sponsors and oversight committees are expected to spell these out before any recruitment begins. (kcl.ac.uk)